El-Hibri Fuad Form 4 August 12, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * El-Hibri Fuad			2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]			5. Relationship of Reporting Person(s) to Issuer			
	(Last)	(First) (Middle)	Ŭ	f Earliest T		(Che	ck all applicab	le)
	` ′	ARCH BLVD., S	ŕ		Day/Year)	Tansacuon	_X_ Director _X_ Officer (gives below)		` ' '
(Street)			4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check			
	ROCKVILI	LE, MD 20850		Filed(Mo	nth/Day/Yea	r)	Applicable Line) _X_ Form filed by Form filed by Person		
	(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative Securities Acq	quired, Disposed o	of, or Beneficia	ally Owned
	1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any (Month/Da	Date, if	3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

	tr. 3)	(Month/Day/Year)	execution Date, if any (Month/Day/Year)	Code (Instr. 8)	(Instr. 3, 4 and 5) (A) or Amount (D) Price		Beneficially Form: Direct Owned (D) or Following Indirect (I) Reported (Instr. 4) Transaction(s) (Instr. 3 and 4)		Beneficial Ownership (Instr. 4)	
Co	mmon ck	08/10/2010		J <u>(1)</u>	205,537	A		1,161,047 (2)	D	
Con	mmon ock	08/10/2010		<u>J(1)</u>	5,417	A	\$ 0	10,428	I	By Karim El-Hibri Trust (3)
Con	mmon ck	08/10/2010		J <u>(1)</u>	5,417	A	\$ 0	10,428	I	By Yusra El-Hibri Trust (3)
Con	mmon ock	08/10/2010		J <u>(1)</u>	5,417	A	\$ 0	10,428	I	By Faiza El-Hibri Trust (3)

Edgar Filing: El-Hibri Fuad - Form 4

Common Stock	6,143,794 (4) I	By Intervac, L.L.C.
Common Stock	1,524,155 (5) I	By Biovac, L.L.C.
Common Stock	2,265,043 (6) I	By BioPharm, L.L.C.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (Instr.	8)	5. In Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)
				Code	v	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships							
• 0	Director	10% Owner	Officer	Other				
El-Hibri Fuad 2273 RESEARCH BLVD., SUITE 400 ROCKVILLE, MD 20850	X	X	CEO and Chairman					

Signatures

/s/ Carl A. Valenstein,
attorney-in-fact 08/11/2010

**Signature of Reporting Person Date

Reporting Owners 2

Edgar Filing: El-Hibri Fuad - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares reported on this line were acquired by a distribution from Intervac, L.L.C.
- (2) Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan that vest in three equal annual installments beginning March 9, 2011.
- These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
 - Mr. El-Hibri holds with his wife, as tenants by the entirety, an aggregate 41.1072% equity interest in Intervac, L.L.C. After the distribution by Intervac, L.L.C. to Mr. El-Hibri and other members of Intervac, L.L.C. of 500,000 shares of Common Stock, as reported
- (4) on this Form 4, Intervac, L.L.C. is the direct owner of 6,143,794 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein in 2,525,543 shares.
- Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, (5) L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
- Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of (6) 2,265,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 909,868 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.